This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sagent Pharmaceuticals Reports First Quarter 2014 Financial Results

SCHAUMBURG, Ill., May 6, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the quarter ended March 31, 2014.

First Quarter 2014 Highlights

  • Revenue increased 18% to a record $70.9 million driven by base business demand and products launched in the last twelve months;
  • Reported gross profit increased 10% to $20.4 million, or 28.8% of net revenue, inclusive of $1.5 million of expense due to unabsorbed manufacturing costs at our SCP facility;
  • Adjusted Gross Profit 1 increased 8% to $20.7 million, or 29.2% of net revenue;
  • Net income of $5.1 million, or diluted earnings per share of $0.16; and
  • Launched Adenosine Injection.

"We are very pleased to report a strong start to the year, with another quarter of record revenue performance driven by broad demand across our diverse product offering," said Jeffrey M. Yordon, chief executive officer and chairman of the board of Sagent. "Demand for our base portfolio was particularly strong, partially driven by market shortages. We were able to leverage the flexibility and responsiveness of our supply chain to support the market need for critical drugs such as heparin."

Financial Results for the Quarter Ended March 31, 2014

Net revenue for the first quarter of 2014 was $70.9 million, an increase of $10.7 million, or 17.7%, compared to $60.2 million in the first quarter of 2013. The increase was driven by $9.7 million in revenue from the launch of 23 new codes or presentations of ten new products since March 31, 2013, and $1.0 million in base business growth, driven by increased demand due to market shortages, partially offset by price declines in zoledronic acid vials, which we launched at market formation in March 2013. Gross profit for the first quarter of 2014 was $20.4 million, or 28.8% of net revenue, inclusive of $1.5 million of expense due to unabsorbed manufacturing costs at our SCP facility, compared to $18.5 million, or 30.7% of net revenue, in the first quarter of 2013. Adjusted gross profit for the first quarter of 2014 was $20.7 million, or 29.2% of net revenue, compared to $19.2 million, or 31.9% of net revenue in the first quarter of 2013.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs